Last reviewed 2026-04-23 · How we verify

R-DA-EPOCH-21 + auto-SCT

R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.

R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant. Used for Diffuse large B-cell lymphoma.

At a glance

Mechanism of action

The R-DA-EPOCH-21 regimen combines the monoclonal antibody rituximab with the EPOCH chemotherapy regimen, which includes etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. The regimen is designed to target and eliminate cancer cells, followed by an autologous stem cell transplant to restore the patient's bone marrow.

Approved indications

• Diffuse large B-cell lymphoma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Infection
• Febrile neutropenia

Key clinical trials

• R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) (PHASE3)
• R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• R-DA-EPOCH-21 + auto-SCT CI brief — competitive landscape report
• R-DA-EPOCH-21 + auto-SCT updates RSS · CI watch RSS
• National Research Center for Hematology, Russia portfolio CI